Cidara Therapeutics, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of long‐acting anti‐infectives and immunotherapies to address life‐threatening fungal, viral and bacterial infections. The company’s core technology platforms, including its proprietary CD‐MONT and Cloudbreak platforms, are designed to create novel therapeutic candidates with extended half‐lives and differentiated mechanisms of action. By leveraging its expertise in macromolecular conjugates and immunotherapeutic design, Cidara seeks to offer new treatment options that can reduce dosing frequency and improve patient outcomes in critical care settings.
The company’s lead asset, rezafungin, is a once‐weekly intravenous echinocandin antifungal in late‐stage development for the prevention and treatment of invasive candidiasis and other serious fungal infections. Rezafungin has been granted Fast Track designation by the U.S. Food and Drug Administration, and Cidara has entered into strategic licensing agreements to support its global commercialization. In addition to rezafungin, Cidara is advancing multiple Cloudbreak immunotherapeutic candidates aimed at combating respiratory viral pathogens, including RSV and coronaviruses, by stimulating the host immune system to mount long‐lasting responses.
Cidara was founded in 2015 and is headquartered in San Diego, California. The company was established by a team of life science entrepreneurs and researchers with deep experience in drug discovery and development. Under the leadership of President and Chief Executive Officer Jeff Stein, Cidara has built a disciplined clinical development strategy and forged collaborative partnerships to accelerate its pipelines through late‐stage trials and regulatory review.
Through collaborations and licensing agreements, Cidara serves markets in North America, Europe and other global territories. The company’s strategic alliances with pharmaceutical partners aim to expand access to its novel anti‐infective and immunotherapy candidates, addressing significant unmet medical needs in immunocompromised and critically ill patient populations.
AI Generated. May Contain Errors.
Free CDTX Stock Alerts